2004714-32-1
Chemical Structure
Hex
- CAS No.: 2004714-32-1
- Formula:C5H10NO5P
- Molecular Weight:195.11
IUPAC Name: (1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid
InChIKey: DVZQUMSQEGOYMX-UHFFFAOYSA-N
SMILES: OP(O)(C1C(N(O)CCC1)=O)=O
Biological Activity: Hex is an enolase inhibitor and antimalarial agent with Ki values of 74.4 nM and 269.4 nM for ENO2 and ENO1, respectively. Hex is a NfENO and TbENO inhibitor with IC50s value of 0.14 μM and 2.1 μM, respectively. Hex has antimalarial activity against Plasmodium falciparum 3D7, Naegleria fowleri trophozoites and Plasmodium berghei ANKA strain. Hex has anti-tumor effects against intracranial tumors[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Hex | 99.07% | Hex is an enolase inhibitor and antimalarial agent with Ki values of 74.4 nM and 269.4 nM for ENO2 and ENO1, respectively. Hex is a NfENO and TbENO inhibitor with IC50s value of 0.14 μM and 2.1 μM, respectively. Hex has antimalarial activity against Plasmodium falciparum 3D7, Naegleria fowleri trophozoites and Plasmodium berghei ANKA strain. Hex has anti-tumor effects against intracranial tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lin YH, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 Dec;2(12):1413-1426. [Content Brief]
- [2]. Milanes JE, et al. Enolase inhibitors as therapeutic leads for Naegleria fowleri infection. PLoS Pathog. 2024 Aug 1;20(8):e1012412. [Content Brief]
- [3]. Roster CP, et al. Enolase Inhibitors as Early Lead Therapeutics against Trypanosoma brucei. Pathogens. 2023 Oct 28;12(11):1290. [Content Brief]
- [4]. Yan VC, et al. Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration. ACS Pharmacol Transl Sci. 2023 Jan 6;6(2):245-252. [Content Brief]
- [5]. Lin Y H, et al. Eradication of ENO1-deleted glioblastoma through collateral lethality. BioRxiv, 2018: 331538.
- [6]. Jezewski A J, et al. Accelerated erythrocyte senescence causes dose-limiting anemia of antimalarial enolase inhibitors. Hematology. American Society of Hematology. Education Program, 2020.
- [7]. Jezewski AJ, et al. Targeting Host Glycolysis as a Strategy for Antimalarial Development. Front Cell Infect Microbiol. 2021 Sep 16;11:730413. [Content Brief]
- [8]. BOARD OF REGENTS, et al. Enolase inhibitors and methods of treatment there with. WO2016145113A1
Keywords
